Filters

Nitrotyrosine Antibody, Cy7 Conjugated

Nitrotyrosine Antibody, Cy7 Conjugated size: 0.1ml 350

Price 350
Size 0.1ml
Long name Cy7 Conjugated, Nitrotyrosine Polyclonal Antibody
CategoryConjugated Primary Antibodies
ConjugationCy7
Host OrganismRabbit (Oryctolagus cuniculus)
Target AntigenNitrotyrosine
SpecificityThis is a highly specific antibody against Nitrotyrosine
ModificationUnmodified
Modification siteNone
ClonalityPolyclonal
ClonePolyclonal antibody
Concentration1ug per 1ul
SourceKLH conjugated to Nitrotyrosine
Tested applications IF(IHC-P), FCM
Recommended dilutions IF(IHC-P)(1:50-200), FCM(1:20-100)
CrossreactivityOthers
Crossreactive species detailsNitrotyrosine
Antigen background Because nitrotyrosine is a stable product of multiple pathways, Nitrotyrosine has been detected in inflammatory processes such as septic shock, atherosclerotic plaques and chronic renal failure, celiac disease, its plasma concentration may be a useful determinant of NO-dependent damage in vivo, rheumatoid arthritis, such as the formation of peroxynitrite, Nitrotyrosine is a marker for inflammation and nitric oxide (NO) production and is formed in the presence of the active metabolite NO
Purification methodThis antibody was purified via Protein A
Storage conditions 50% glycerol and 0, Store refrigerated at 2 to 8 degrees Celcius for up to 1 year, 09% sodium azide, Keep the antibody in an aqueous buffered solution containing 1% BSA
Excitation Emission743nm/767nm
SynonymsNULL
PropertiesC, C for long term storage and for short term at + 5°, If you buy Antibodies supplied by Bioss Primary Conjugated Antibodies they should be stored frozen at - 24°
ConjugatedThese antibodies are excite for emission at 650 nm and detected at a 676 nm wavelengths
Gene targetNitrotyrosine Conjugated
Short name Conjugated, Nitrotyrosine Antibody
Technique antibodies against human proteins, antibodies for, antibody Conjugates, Antibody
LabelCy7
Alternative name cyanine 7 coupled, Nitrotyrosine (Antibody to)
Alternative techniqueantibodies

Subscribe to our Newsletter